VERAXA Biotech (NASDAQ: VRXA) is highlighting partnering opportunities for its proprietary BiTAC-ADC and BiTAC-TCE technology platforms ahead of the BIO International Convention, taking place June 22-25 in San Diego. The company recently reported new proof-of-concept data supporting its BiTAC-ADC platform, which is designed to improve cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity.
VERAXA said the findings, together with previously presented BiTAC-TCE data unveiled at the American Association for Cancer Research Annual Meeting in April 2026, support the potential of two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both technologies at the BIO International Convention, scheduled for June 22-25, 2026, in San Diego.
The full press release is available at https://ibn.fm/r8zEz. VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. This announcement is significant because it underscores VERAXA's progress in developing platforms that could address key challenges in oncology, such as off-target toxicity, and opens the door for collaborations that may accelerate the development of these therapies. The BIO International Convention serves as a critical venue for biotech companies to forge partnerships, and VERAXA's active pursuit of partners suggests confidence in the commercial potential of its BiTAC platforms.
Forward-looking statements in this article are based on current expectations and assumptions, and actual results may differ materially due to risks and uncertainties. These include factors discussed under "Risk Factors" in the company's filings with the SEC. The company undertakes no duty to update this information unless required by law.
